34 results on '"DeBay, Drew R."'
Search Results
2. No difference in cerebral perfusion between the wild-type and the 5XFAD mouse model of Alzheimer’s disease
3. Butyrylcholinesterase as a biomarker in Alzheimer’s disease
4. Contributors
5. NEMA NU 1-2018 performance characterization and Monte Carlo model validation of the Cubresa Spark SiPM-based preclinical SPECT scanner
6. Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease
7. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI
8. IC-P-136: SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1-METHYL-4-PIPERIDYL P- 18 [F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE-SPECIFIC RADIOLIGAND FOR ALZHEIMER'S DISEASE
9. P2-402: SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1-METHYL-4-PIPERIDYL P- 18 [F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE-SPECIFIC RADIOLIGAND FOR ALZHEIMER'S DISEASE
10. P1‐424: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE
11. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimer’s disease
12. [P1-353]: CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER's DISEASE
13. [IC-P-023]: CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER's DISEASE
14. Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer’s Disease
15. SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1-METHYL-4-PIPERIDYL P-18[F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE-SPECIFIC RADIOLIGAND FOR ALZHEIMER’S DISEASE
16. P3-261: Synthesis and IN VIVO Spect Evaluation of a Novel Butyrylcholinesterase Diagnostic Radioligand for Alzheimer’S Disease
17. IC-P-163: Synthesis and In Vivo Spect Evaluation of a Novel Butyrylcholinesterase Diagnostic Radioligand for Alzheimer’s Disease
18. Using lymph node swelling as a potential biomarker for successful vaccination
19. BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER’S DISEASE
20. IC‐P‐065: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE.
21. IC-P-022: Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer's disease
22. P1-160: Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer's disease
23. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines
24. CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER’S DISEASE
25. P1-296: ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE
26. IC-P-098: ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE
27. SYNTHESIS AND IN VIVO SPECT EVALUATION OF A NOVEL BUTYRYLCHOLINESTERASE DIAGNOSTIC RADIOLIGAND FOR ALZHEIMER’S DISEASE
28. ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE
29. P2‐402: SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1‐METHYL‐4‐PIPERIDYL P‐18[F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE‐SPECIFIC RADIOLIGAND FOR ALZHEIMER'S DISEASE.
30. IC‐P‐065: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE.
31. Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer’s disease.
32. Combined PET/MR: Where Anatomical Imaging Meets Cellular Function.
33. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves 18 FDG retention in 5XFAD mouse model of Alzheimer's disease.
34. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.